Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.Semaglutide 2.4 mg injection (Wegovy ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Investors eyed risks around a high-stakes US-Ukraine meeting, kicking off a week dominated by a Federal Reserve speech that ...

Shares in Danish pharma company Novo Nordisk jumped after it halved the out-of-pocket price of Ozempic in the US and gained ...